RxDoctor Payments Data

John Green, MD

Obstetrics & Gynecology · Elizabethton, TNNPI 1659486900

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $874,852 of the $877,958 with a category attached, or 99.6%. Medtronic accounts for 99.7% of it on its own, with 9 other manufacturers making up the rest. Among obstetrics & gynecology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$877,958in general payments, 2019–2025

Across 24 payments — averaging $36,582 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$875K
  • Organon$3K
  • Astellas Pharma US Inc$114
  • Avion Pharmaceuticals$46
  • AbbVie$43
  • Sumitomo Pharma America, Inc.$36
  • plus $67 from 4 others

What the payments were for

  • Royalty or licence$874,852100%
  • Speaking & faculty fees$2,7500%
  • Food & beverage$2200%
  • Education$1360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$877,958 in reported general payments places this provider in the 95th percentile of 763 obstetrics & gynecology providers in Tennessee.

See all obstetrics & gynecology providers in Tennessee

Medicare billing

Part B allowed, 2024
$11,952
Medicare patients
47
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron75$41,983
ElmironPentosan Polysulfate Sodium17$15,624
Tetracycline Hcl11$3,184
Tolterodine Tartrate ErTolterodine Tartrate25$1,769
Estradiol61$1,732
Oxybutynin Chloride28$735
Medroxyprogesterone Acetate45$617
Clobetasol Propionate26$588
NitrofurantoinNitrofurantoin Macrocrystal14$308
Hydroxyzine Hcl11$282
Gabapentin13$152
Prochlorperazine Maleate19$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$114$41,98375 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 763 obstetrics & gynecology providers in Tennessee.

Other obstetrics & gynecology in Elizabethton

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →